A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains after completion of vaccination course.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

NCT00314145

Japanese Encephalitis

COMPLETED PHASE3

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

NCT00314132

Encephalitis Japanese Encephalitis

COMPLETED PHASE3

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

NCT00981175

Encephalitis Japanese Encephalitis

COMPLETED PHASE2

Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

NCT00981630

Japanese Encephalitis

COMPLETED PHASE2

Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age

NCT00441259

Japanese Encephalitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Japanese Encephalitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ChimeriVax™-JE

Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.

Group Type EXPERIMENTAL

ChimeriVax™-JE vaccine

Intervention Type BIOLOGICAL

0.5 mL, subcutaneously

JE-VAX®

Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.

Group Type ACTIVE_COMPARATOR

JE-VAX® vaccine

Intervention Type BIOLOGICAL

1.0 mL, subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ChimeriVax™-JE vaccine

0.5 mL, subcutaneously

Intervention Type BIOLOGICAL

JE-VAX® vaccine

1.0 mL, subcutaneously

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ChimeriVax™-JE JE-VAX®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained.
* Aged ≥18 to \<49 years.
* In good general health.
* Available for the study duration, including all planned follow-up visits.
* Females must have negative pregnancy test and be using adequate form of contraception

Exclusion Criteria

* Clinically significant abnormalities on laboratory and vital sign assessments.
* Anaphylaxis or other serious adverse reactions
* Administration of another vaccine within 30 days of study treatment period.
* Physical examination indicating any significant medical condition.
* Intention to travel out of the area prior to the study visit on Day 56.
* Seropositive to Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) or positive for Hepatitis B Surface Antigen.
* Pregnancy.
* Excessive alcohol consumption, drug abuse.
* Involvement in another clinical study within 60 days preceding the screening visit and during study treatment period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

48 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes